Yang Su-Jin, Yang Su-Yu, Wang Dan-Dan, Chen Xiu, Shen Hong-Yu, Zhang Xiao-Hui, Zhong Shan-Liang, Tang Jin-Hai, Zhao Jian-Hua
1 The Fourth Clinical School of Nanjing Medical University, Nanjing, China.
2 Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, China.
Tumour Biol. 2017 Mar;39(3):1010428317692204. doi: 10.1177/1010428317692204.
The microRNA family, miR-30, plays diverse roles in regulating key aspects of neoplastic transformation, metastasis, and clinical outcomes in different types of tumors. Accumulating evidence proves that miR-30 family is pivotal in the breast cancer development by controlling critical signaling pathways and relevant oncogenes. Here, we review the roles of miR-30 family members in the tumorigenesis, metastasis, and drug resistance of breast cancer, and their application to predict the prognosis of breast cancer patients. We think miR-30 family members would be promising biomarkers for breast cancer and may bring a novel insight in molecular targeted therapy of breast cancer.
微小RNA家族miR-30在调控不同类型肿瘤的肿瘤转化、转移及临床结局的关键方面发挥着多种作用。越来越多的证据表明,miR-30家族通过控制关键信号通路和相关癌基因在乳腺癌发展过程中起关键作用。在此,我们综述了miR-30家族成员在乳腺癌发生、转移及耐药中的作用,以及它们在预测乳腺癌患者预后方面的应用。我们认为miR-30家族成员有望成为乳腺癌的生物标志物,并可能为乳腺癌的分子靶向治疗带来新的见解。